Barlic Jana, Sechler Joan M, Murphy Philip M
molecualr Signalling Section, Laboratory of Host Defenses, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Blood. 2003 Nov 15;102(10):3494-503. doi: 10.1182/blood-2003-03-0946. Epub 2003 Jul 24.
The chemokine receptor CX3CR1 (CX3C chemokine receptor 1) is expressed in mouse blood on natural killer (NK) cells and on monocytes. Because interleukin-15 (IL-15) is an essential cytokine for NK cell development and maintenance, we hypothesized that it may induce CX3CR1 expression on this cell type. In contrast, we found that in primary mouse bone marrow-derived NK cells IL-15 specifically inhibited CX3CR1 protein and mRNA accumulation, whereas the related cytokine IL-2 did not inhibit but instead increased CX3CR1 expression. Consistent with this finding, intravenous injection of a single dose of recombinant IL-15 into C57BL/6 mice decreased steady-state CX3CR1 levels 24 hours after injection in freshly isolated peripheral blood mononuclear cells (PBMCs), splenocytes, and bone marrow cells, and treatment of mouse PBMCs with IL-15 in vitro inhibited CX3CL1 (ligand for CX3CR1)-induced chemotaxis. These data suggest that IL-15 may be a negative regulator of innate immunity by inhibiting CX3CR1 expression. These data also suggest that IL-15 inhibition of CX3CR1 may subvert potential cell immunotherapy strategies in which IL-15 is used to expand NK cell populations in vivo or ex vivo. Finally, our results provide additional evidence for differential signaling by IL-2 and IL-15, despite usage of common beta gamma c receptor chains.
趋化因子受体CX3CR1(CX3C趋化因子受体1)在小鼠血液中的自然杀伤(NK)细胞和单核细胞上表达。由于白细胞介素15(IL-15)是NK细胞发育和维持所必需的细胞因子,我们推测它可能诱导这种细胞类型上CX3CR1的表达。然而,我们发现,在原代小鼠骨髓来源的NK细胞中,IL-15特异性抑制CX3CR1蛋白和mRNA的积累,而相关细胞因子IL-2并未抑制反而增加了CX3CR1的表达。与此发现一致,向C57BL/6小鼠静脉注射单剂量重组IL-15后,在新鲜分离的外周血单核细胞(PBMC)、脾细胞和骨髓细胞中,注射后24小时稳态CX3CR1水平降低,并且在体外用IL-15处理小鼠PBMC可抑制CX3CL1(CX3CR1的配体)诱导的趋化作用。这些数据表明,IL-15可能通过抑制CX3CR1的表达而成为先天免疫的负调节因子。这些数据还表明,IL-15对CX3CR1的抑制可能会破坏潜在的细胞免疫治疗策略,即在体内或体外使用IL-15来扩增NK细胞群体。最后,尽管使用了共同的βγc受体链,但我们的结果为IL-2和IL-15的差异信号传导提供了额外的证据。